Alternative to Lenalidomide ID'd for Maintenance in Multiple Myeloma
Body Mass Index Tied to Multiple Myeloma Survival
Inflammatory-Nutritional Score Helps Predict Survival in New Multiple Myeloma
Mass Spectrometry Can Monitor Treatment Response in Multiple Myeloma
About Half Have Meaningful Drop in Long COVID Symptoms by 36 Months
Genetic Screening Can ID Hemoglobinopathy Prevalence
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus
Nonpharmacologic Therapy Cuts Opioid Use Disorder Risk With Low Back Pain
Alternative to Lenalidomide ID'd for Maintenance in Multiple Myeloma 
Body Mass Index Tied to Multiple Myeloma Survival 
Inflammatory-Nutritional Score Helps Predict Survival in New Multiple Myeloma 
About Half Have Meaningful Drop in Long COVID Symptoms by 36 Months 
Genetic Screening Can ID Hemoglobinopathy Prevalence 
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus 
Nonpharmacologic Therapy Cuts Opioid Use Disorder Risk With Low Back Pain 
